Johnson & Johnson (NYSE:JNJ) Shares Purchased by Garde Capital Inc.

Garde Capital Inc. lifted its position in Johnson & Johnson (NYSE:JNJ) by 16.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,084 shares of the company’s stock after purchasing an additional 300 shares during the period. Garde Capital Inc.’s holdings in Johnson & Johnson were worth $327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. American Trust raised its position in Johnson & Johnson by 2.9% during the fourth quarter. American Trust now owns 43,881 shares of the company’s stock worth $6,878,000 after acquiring an additional 1,246 shares during the period. V Square Quantitative Management LLC raised its position in Johnson & Johnson by 83.2% during the fourth quarter. V Square Quantitative Management LLC now owns 33,117 shares of the company’s stock worth $5,191,000 after acquiring an additional 15,039 shares during the period. Novak & Powell Financial Services Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth $1,588,000. GLOBALT Investments LLC GA acquired a new position in Johnson & Johnson during the fourth quarter worth $3,171,000. Finally, Able Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $67,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.1 %

JNJ stock opened at $145.54 on Friday. The company has a fifty day moving average price of $148.38 and a 200 day moving average price of $154.67. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The company has a market cap of $350.27 billion, a price-to-earnings ratio of 9.07, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the prior year, the firm earned $2.68 EPS. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.41%. Johnson & Johnson’s dividend payout ratio is 30.92%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on JNJ. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, May 6th. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 10th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. The Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price for the company. Finally, Morgan Stanley reduced their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Eight analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Hold” and a consensus target price of $174.07.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.